Today: Today, Neurocrine Biosciences Inc. (NBIX) Earns “Outperform” Rating from Leerink Swann

Today, Neurocrine Biosciences Inc. (NBIX) Earns “Outperform” Rating from Leerink Swann

Leerink Swann restated their outperform rating on shares of Neurocrine Biosciences Inc. (NASDAQ:NBIX) in a research report released on Wednesday morning. The firm currently has a $70.00 price target on the stock.

NBIX has been the subject of several other research reports. Jefferies Group reaffirmed a buy rating and set a $61.00 target price on shares of Neurocrine Biosciences in a research note on Friday, September 23rd. HC Wainwright reaffirmed a buy rating on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Piper Jaffray Cos. reaffirmed an overweight rating and set a $96.00 target price on shares of Neurocrine Biosciences in a research note on Thursday, September 22nd. Cowen and Company reaffirmed a buy rating and set a $65.00 target price on shares of Neurocrine Biosciences in a research note on Friday, August 5th. Finally, TheStreet cut Neurocrine Biosciences from a hold rating to a sell rating in a research note on Thursday, July 14th. One research analyst has rated the stock with a sell rating and ten have assigned a buy rating to the stock. The stock has a consensus rating of Buy and a consensus price target of $65.50.

Shares of Neurocrine Biosciences (NASDAQ:NBIX) opened at 42.30 on Wednesday. Neurocrine Biosciences has a 52 week low of $31.25 and a 52 week high of $58.46. The company’s market cap is $3.67 billion. The stock’s 50 day moving average price is $49.92 and its 200-day moving average price is $47.80.

In related news, insider Christopher Flint Obrien sold 12,500 shares of Neurocrine Biosciences stock in a transaction on Monday, August 15th. The stock was sold at an average price of $48.73, for a total transaction of $609,125.00. Following the sale, the insider now directly owns 55,044 shares in the company, valued at $2,682,294.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Corinne H. Nevinny sold 5,000 shares of Neurocrine Biosciences stock in a transaction on Monday, August 8th. The stock was sold at an average price of $48.54, for a total value of $242,700.00. Following the sale, the director now owns 25,555 shares in the company, valued at $1,240,439.70. The disclosure for this sale can be found here. Corporate insiders own 4.80% of the company’s stock.

A number of hedge funds have recently modified their holdings of the company. Creative Planning raised its stake in shares of Neurocrine Biosciences by 0.7% in the third quarter. Creative Planning now owns 5,338 shares of the company’s stock worth $270,000 after buying an additional 38 shares during the period. Natixis raised its stake in shares of Neurocrine Biosciences by 0.7% in the first quarter. Natixis now owns 8,891 shares of the company’s stock worth $352,000 after buying an additional 66 shares during the period. Mutual of America Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 0.3% in the second quarter. Mutual of America Capital Management LLC now owns 71,904 shares of the company’s stock worth $3,268,000 after buying an additional 200 shares during the period. Springbok Capital Management LLC raised its stake in shares of Neurocrine Biosciences by 5.5% in the first quarter. Springbok Capital Management LLC now owns 7,061 shares of the company’s stock worth $279,000 after buying an additional 367 shares during the period. Finally, BNP Paribas Arbitrage SA raised its stake in shares of Neurocrine Biosciences by 4.8% in the second quarter. BNP Paribas Arbitrage SA now owns 12,736 shares of the company’s stock worth $579,000 after buying an additional 583 shares during the period. Institutional investors and hedge funds own 96.71% of the company’s stock.

Neurocrine Biosciences Company Profile

Related posts

Leave a Comment